Caption Management’s Denali Therapeutics DNLI Stock Holding History

Caption Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.43M	Buy	+74,600	New	+$1.48M	0.01%	913
2025 Q4	–	Sell	-30,000	Closed	-$436K	–	1684
2025 Q3	$436K	Buy	+30,000	New	+$431K	﹤0.01%	1332
2025 Q1	–	Sell	-30,000	Closed	-$611K	–	1646
2024 Q4	$611K	Buy	+30,000	New	+$768K	0.01%	1044
2024 Q3	–	Sell	-30,000	Closed	-$697K	–	1365
2024 Q2	$697K	Buy	+30,000	New	+$576K	0.01%	745
2024 Q1	–	Sell	-30,000	Closed	-$644K	–	1311
2023 Q4	$644K	Hold	30,000	–	–	0.01%	900
2023 Q3	$619K	Buy	+30,000	New	+$761K	0.01%	888
2022 Q1	–	Sell	-30,000	Closed	-$1.34M	–	1565
2021 Q4	$1.34M	Sell	30,000 -26,200	-47%	-$1.24M	0.02%	935
2021 Q3	$2.83M	Buy	56,200 +26,200	+87%	+$1.48M	0.03%	635
2021 Q2	$2.35M	Buy	+30,000	New	+$1.86M	0.03%	630
2021 Q1	–	Sell	-37,500	Closed	-$3.14M	–	1128
2020 Q4	$3.14M	Buy	+37,500	New	+$2.27M	0.07%	330

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's DNLI Position: Q4 2025 in Review

Caption Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 7,366 shares — an estimated $107K sold.

Caption Management first reported a position in DNLI in Q4 2023 and held it in 3 quarters. The position peaked at $406K in Q4 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Caption Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 7,366 Denali Therapeutics shares in Q4 2025, an estimated $107K.
Caption Management first reported a position in Denali Therapeutics in Q4 2023 and held it in 3 quarters.
Caption Management's Denali Therapeutics position peaked at $406K in Q4 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.